摘要
目的 比较不同治疗方法对肝细胞癌伴门静脉癌栓的治疗效果。方法 回顾分析 84例肝细胞癌合并门静脉癌栓患者的临床资料。按不同治疗方法分成 5组 :手术切除 +癌栓取出 +术后肝动脉化疗栓塞术 (TACE)和胸腺肽治疗组 (A组 ) 9例 ;手术切除 +癌栓取出 +术后TACE治疗组(B组 ) 2 0例 ;手术切除 +癌栓取出组 (C组 ) 7例 ;TACE治疗组 (D组 ) 38例 ;保守治疗组 (E组 ) 10例。比较各组癌栓变化和生存期。结果 A、B、C、D、E各组对癌栓治疗有效率分别为 6 6 .7%、70 .0 %、5 7.1%、7.9%和 0 ,中位生存期分别为 10 .0 ,7.0 ,8.0 ,5 .0和 2 .0个月 ,1年生存率分别为4 4 .4 %、15 .0 %、14 .3%、10 .5 %和 0。结论 手术切除 +癌栓取出术可清除大部分癌栓 ,术后TACE可进一步提高患者的生存率。
Objective To investigate the effects of different treatments for hepatocellular carcinoma(HCC) with tumor thrombus in the portal vein(PVTT). Methods From Jan. 2000 to Jan. 2003, a total of 84 HCC patients with PVTT were divided into five groups based on methed of treatment: Group A( n =9), HCC resection+PVTT removal+postoperative TACE+thymosin α 1; Group B ( n =20), HCC resection+PVTT removal+postoperative TACE; Group C ( n =7), HCC resection+PVTT removal; Group D ( n =38), TACE only; Group E ( n =10), conservative treatment only. Results The rate of PVTT shrinkage or disappearance of groups A, B, C, D and E was 66.7%,70.0%, 57.1%, 7.9% and 0, respectively with respective median survival time of 10.0, 7.0, 8.0, 5.0 and 2.0 months. The one year survival rate was 44.4%, 15.0%, 14.3%, 10.5% and 0. Conclusion Resection of HCC and removal of tumor thrombus in the portal vein may have the tumor thrombus cleared in most of the patients and postoperative TACE and thymisin α 1 treatment may improve their survival.
出处
《中华肿瘤杂志》
CAS
CSCD
北大核心
2005年第3期183-185,共3页
Chinese Journal of Oncology
基金
上海市科技发展基金资助项目 (0 4QMH14 0 8)
医苑新星培养计划
